Company: BGLC
Filing Date: 2025-11-14
Form Type: 10-Q
Source: 0001477932-25-008343
Chunk: 33

Company: BioNexus Gene Lab Corp
Filing Date: 2025-11-14
Form: 10-Q
Item: Part I, Item 1
Chunk 33
---
 the financial information concerning the Company’s reportable segments is shown as below:

 25Table of Contents

BIONEXUS GENE LAB CORP. 

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2025 AND 2024 

(Currency expressed in United States Dollars (“US$”)) 

(Unaudited)

Segmented Information   Provision for genomic screening services  Trading of industrial chemicals  Investment holding  Total   Three months for period ended September 30, 2024              REVENUE $2,563  $2,627,813  $-  $2,630,376                  COST OF REVENUE  (2,118)  (2,301,722)  -   (2,303,840)                 GROSS PROFIT  445   326,091   -   326,536                  OTHER INCOME                Dividend income   -   38,826   -   38,826 Interest income  19,224   15,798   -   35,022 Fair value gain on investments in equity securities  -   69,766   -   69,766 Gain on disposal of investments in equity securities  -   20,800   -   20,800 Reversal of expected credit losses  -   257,986   -   257,986 Others  3,548   39,579   -   43,127 TOTAL OTHER INCOME  22,772   442,755   -   465,527                  OPERATING EXPENSES                Sales and marketing  (24,625)  (1,195,502)  (25,329)  (1,245,456)Research and development  (10,442)  -   -   (10,442)General and administrative  (255,477)  (175,667)  (361,269)  (792,413)Fair value loss on investments in equity securities  -   (79,000)  -